gefitinib has been researched along with sr 48692 in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (sr 48692) | Trials (sr 48692) | Recent Studies (post-2010) (sr 48692) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 203 | 3 | 36 |
| Protein | Taxonomy | gefitinib (IC50) | sr 48692 (IC50) |
|---|---|---|---|
| Neurotensin receptor type 1 | Rattus norvegicus (Norway rat) | 0.082 | |
| Neurotensin receptor type 1 | Homo sapiens (human) | 0.0415 | |
| Sortilin | Homo sapiens (human) | 0.238 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Chan, DC; Jensen, RT; Mantey, SA; Moody, TW; Moreno, P | 1 |
2 other study(ies) available for gefitinib and sr 48692
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Pyrazoles; Quinazolines; Quinolines; Receptors, Neurotensin; RNA, Small Interfering; Transcriptional Activation; Transforming Growth Factor alpha | 2014 |